A progressively enlarging cerebellar hematoma concurrent with T-DM1 treatment. Case report
Trastuzumab emtansine, an antibody –drug conjugate commonly abbreviated as T-DM1, is accepted as an effective therapy for trastuzumab-resistant metastatic HER2-positive breast cancer. T-DM1 significantly increases progression-free and overall survival when compared to lapatinib plus capecitabine in patients with HER2-positive breas t cancer previously treated with trastuzumab and a taxane. Among the common side effects related to T-DM1, thrombocytopenia and mucosal hemorrhage are seen, although they are infrequently judged to be clinically significant.
Source: World Neurosurgery - Category: Neurosurgery Authors: Marcelo D. Vilela, William T. Longstreth, Hugo AS. Pedrosa, Gabriel OB. Gil, Juliano M. Duarte, Marco Antonio D. Filho Tags: Case Report Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Neurology | Neurosurgery | Thrombocytopenia | Xeloda